BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, November 22, 2024
See today's BioWorld
Home
» Week in review for Feb. 24-28, 2020: Two migraine therapies approved
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full article
sign up for free
or
sign in
.
Week in review for Feb. 24-28, 2020: Two migraine therapies approved
March 2, 2020
By
Peter Winter
No Comments
A quick look back at top stories, including: 1st Biotherapeutics, Acacia, Apeiron, Ascletis, Axovant, Bicycle, Biogen, Biohaven, Boehringer Ingelheim, Cocrystal, Curis, Glaxosmithkline, H. Lundbeck, Makscientific, MPM, NGM, Oramed, Pvp, Redhill, Roche, Sangamo, Shenzhen Xtalpi, Sichuan Clover, Steba, Takeda, Tetra, Tonix, Trutino, Twoxar, Vir, Wuxi.
BioWorld
Analysis and data insight
Coronavirus